A new cancer treatment that delivers radiation directly to tumors by targeting two key markers simultaneously has been shown to be safe and effective in human trials. Acting like a “smart missile,” the dual-targeting radiopharmaceutical is designed to attach to two vulnerable sites on cancer cells, enabling more precise and potent therapy. Early results show that nearly 90% of patients experienced either tumor shrinkage or disease stabilization. These findings were presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting.